To predict the safety of a drug at an early stage in its development is a major challenge as
there is a lack of in vitro heart models that correlate data from preclinical toxicity screening …

Aims Reliable defibrillation with reduced energy deposition has long been the focus of
defibrillation research. We studied the efficacy of single shocks of 300 ns duration in …

Aims Na+ channel blockers are often used to treat atrial fibrillation (AF), but may sometimes
cause ventricular contractile dysfunction. However, amiodarone, a multi-channel blocker …

Ventricular fibrillation (VF) causes failure of synchronous contraction of the heart ventricles,
resulting in cardiac collapse. Currently, VF is still the major cause of sudden cardiac death …

Background: In Japan, intravenous nifekalant (NIF) was often used for direct current
cardioversion-resistant ventricular fibrillation (VF), until the use of intravenous amiodarone …

Background: Low-voltage zones (LVZs) were usually targeted for ablation in atrial fibrillation
(AF). However, its relationship with AF initiation, perpetuation, and termination remains to be …

Background Amiodarone is administered during resuscitation, but its antiarrhythmic effects
during targeted temperature management are unknown. The purpose of this study was to …

Aims To determine the spectral dynamics of early spontaneous polymorphic ventricular
tachycardia and ventricular fibrillation (PVT/VF) in humans. Methods and results Fifty-eight …

With special attention, we have read the letter from Dr Warren and Dr Zaitsev. In their letter,
they react on our recent publication in Cardiovascular Research, 1 in which we used four …

Background: In patients with shock refractory out-of-hospital cardiac arrest (OHCA),
antiarrhythmic drugs are used to improve the defibrillation success and/or prevent re …